Quantcast
Last updated on April 19, 2014 at 7:48 EDT

Latest Novocure Limited Stories

2013-04-10 08:32:40

New Data Describes the Efficacy of NovoTTF(TM) Therapy in Combination with Chemotherapy in Preclinical Solid Tumor Models WASHINGTON, April 10, 2013 /PRNewswire/ -- Novocure announced today that new data from preclinical testing of NovoTTF Therapy in non-small cell lung carcinoma (NSCLC), ovarian and pancreatic cancer has been presented at the 2013 AACR Annual Meeting. The new data builds on existing published research describing the potential efficacy of NovoTTF Therapy in a wide...

2013-01-22 12:27:50

ST. HELIER, Jersey, Jan. 22, 2013 /PRNewswire/ -- Novocure Limited announced today that Novocure's NovoTTF(TM) Therapy has been added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers. The new NCCN Guidelines® indicate that physicians consider using NovoTTF Therapy as a new option, in addition to surgery, chemotherapy, and radiation, for patients with glioblastoma brain tumors that recur or progress after initial treatment. The...

2013-01-08 12:26:34

ST. HELIER, Jersey, Jan. 8, 2013 /PRNewswire/ -- Novocure Limited announced today the appointment of Louis J. Lavigne Jr., James T. Lenehan, Robert J. Mylod Jr. and Charles G. Phillips III to its board of directors. The new members are independent directors and provide Novocure extensive financial and healthcare industry expertise. Novocure is a private, commercial stage oncology company dedicated to the development and commercialization of NovoTTF(TM) Therapy, its novel and proprietary...

2012-11-14 12:26:45

PORTSMOUTH, N.H., Nov. 14, 2012 /PRNewswire/ -- Novocure(TM), a commercial stage private oncology company, announced today that preclinical and clinical data from studies evaluating NovoTTF(TM) Therapy will be presented at the 17th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) in Washington, D.C. The data presented sheds light on the subcellular mechanisms underlying the anti-cancer effect of NovoTTF Therapy and helps define which recurrent GBM...

2012-05-24 06:27:55

PORTSMOUTH, N.H., May 24, 2012 /PRNewswire/ -- Novocure(TM), a commercial stage private oncology company, announced that by June 1, eight additional clinical centers of excellence will join the seven existing clinical centers that provide Novocure's Tumor Treating Fields (TTFields) therapy to patients with recurrent GBM. These fifteen clinical centers are among the leading cancer centers in the U.S. GBM is both the deadliest and most common form of primary brain tumor in the U.S., diagnosed...

2012-05-21 06:25:01

PORTSMOUTH, N.H., May 21, 2012 /PRNewswire/ -- Results of the first randomized controlled trial to compare a novel cancer treatment modality delivering Tumor Treating Fields (TTFields) therapy versus chemotherapy in patients with recurrent glioblastoma (GBM) were published in the European Journal of Cancer (Stupp R. et al., NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomized phase III trial of a novel treatment modality, Eur J...

2012-05-14 06:27:14

PORTSMOUTH, N.H., May 14, 2012 /PRNewswire/ -- In its ongoing effort to help patients, their caregivers and health care professionals easily find detailed information about its NovoTTF(TM) therapy for recurrent glioblastoma, Novocure(TM) today unveiled its U.S.-focused NovoTTF(TM) Therapy Website, found at www.novottftherapy.com. Novocure(TM), a commercial stage private oncology company, manufactures the NovoTTF(TM)-100A,( )a wearable device that delivers tumor treating fields...

2011-12-16 12:15:00

PORTSMOUTH, N.H., Dec. 16, 2011 /PRNewswire/ -- Novocure, a commercial stage private oncology company, announced today the addition of three former senior OSI Pharmaceuticals executives to its Global Commercialization Team. The Global Commercialization Team is responsible for bringing the company's new tumor treating fields (TTF) cancer therapy to patients worldwide. Peter M. Melnyk has joined Novocure as chief commercial officer responsible for directing the company's global...

2011-12-02 08:00:00

PORTSMOUTH, N.H., Dec. 2, 2011 /PRNewswire/ -- Novocure(TM), a commercial stage private oncology company, has announced that prominent neuro-oncologists at four clinical centers in the U.S. will be the first to provide access to its Tumor Treating Fields (TTFields)(TM) device, NovoTTF-100A System(TM), for the treatment of recurrent glioblastoma multiforme (GBM). GBM is a deadly brain tumor affecting approximately 10,000 Americans each year. The NovoTTF(TM) device, approved by...

2011-11-21 08:00:00

ANAHEIM, Calif., Nov. 21, 2011 /PRNewswire/ -- Novocure(TM), a commercial stage private oncology company, announced today that Dr. Eric T. Wong, Co-Director, Brain Tumor Center, Beth Israel Deaconess Medical Center in Boston, presented follow-up results of a study focusing on overall survival in patients with recurrent glioblastoma multiforme (GBM). The long-term follow-up results from the Phase III EF-11 study compared overall survival at two and three years after initiating therapy in...